The AHA, American Medical Association, American Society of Health-System Pharmacists, and United States Pharmacopeia last week convened a virtual summit to examine the resilience of the U.S. pharmaceutical supply chain in light of the current state of global pharmaceutical manufacturing.

Representatives from clinician groups, industry, the supply chain and public sector discussed global pharmaceutical manufacturing as a national security priority, noting that the rapid global outbreak of COVID-19 and its negative ripple effect on patients’ access to critical medicines have called attention to increasing concerns about the stability and security of the U.S. drug supply.

Summit topics included advanced technologies such as continuous manufacturing and 3-D printing, which may help produce oral and parenteral drugs more efficiently; the role of public-private partnerships in developing and disseminating new technologies; diversifying the global supply chain; and creating a list of essential medicines to produce in the U.S.

The organizers plan to release a report outlining the summit proceedings later this year.

Related News Articles

Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Chairperson's File
Public
Most hospitals and health systems are the largest organizations in our communities, providing critical services needed by every one of our neighbors. We take…
Headline
The AHA May 16 urged the Department of Commerce to consider tariff exceptions for critical minerals and derivative products used for medical purposes. Critical…
Headline
The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In…
Headline
The U.S. and China reached a joint agreement to temporarily reduce tariffs for 90 days, the White House announced May 12. Both countries will lower tariffs by…
Headline
AHA today submitted comments to the Department of Commerce on its Section 232 national security investigation of pharmaceutical and pharmaceutical ingredients…